About

RC48G001 is a phase 2, open-label, multi-cohort study of disitamab vedotin (DV) alone or with Pembrolizumab in adults with locally advanced unresectable or metastatic urothelial cancer that expresses HER2.

Participants with the following types of urothelial cancer may be eligible:

  • Cohort C: treatment-naive participants with LA/mUC
  • Cohort G: participant with LA/mUC previously treated with enfortumab vedotin

Get started

Answer a 2-minute questionnaire and speak to a study representative.

A first step as you consider connecting with a Principal Investigator is to answer a 2-minute online questionnaire about your interest and willingness to be contacted. If your answers show the study might be a good fit for you and your patient, you may choose to have your contact information shared with a study clinic that you select for further discussion.

Get connected.

Your answers to these questions will only be linked to you if your responses indicate that you would like to be connected with a Principal Investigator and you choose to share your contact information with the study clinic. Pfizer study team members and our partners will have access to reports containing aggregated data that will not be directly linked back to you. Only the study staff can determine if your patient meets the study’s eligibility criteria and is able to enroll in the study.

Is this page helpful?